Alluvi, previously BI 4744, presents a significant breakthrough in obesity care. This dual agonist targeting both glucagon-like peptide-1 and GIP targets demonstrates compelling effectiveness in research trials, https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/